Event info
Date:03 Mar
Time:08:30 to 15:30
Venue:Ørestad, Denmak

Scottish Stem Cell & Regenerative Medicine Seminar: Insights and opportunities for Scotland and the Nordics

Medicon Valley Alliance in cooperation with Scottish Development International (SDI) are delighted to welcome you to participate in an exclusive seminar and partnering meeting, gathering the best of Scotland’s stem cell and regenerative medicine industry.
This high-level seminar and partnering meeting, will showcase key speakers from Scotland’s dynamic regenerative medicine community giving you the opportunity to see why it’s one of Europe’s leading stem cell hubs.
Following the morning’s speakers, Scottish and Nordic biotechnology companies will participate in a networking lunch with a further opportunity for dedicated one-to-one meetings with Scottish companies in the afternoon. This seminar is an ideal and unique chance to network and establish new contacts at a senior and specialised level between Scotland and the Nordics.
The seminar is open to biotech and pharma companies and investors within the life science industry.
Date: March 3, 2014
Time: 8:30 – 15:30
Venue: Edvard Thomsens Vej 14, DK-2300 Copenhagen S
Room: Auditorium
 
Program
08.30-09.00 Registration: coffee/tea/breakfast
09.00-09.10 SDI: Welcome to Scottish Stem Cell & Regenerative Medicine Seminar. View the presentation here.
09.10-09.30 Sistemic: The role of improved product characterization on the development and approval of cell therapy products
09.30-09.50 Clyde Biosciences: Preclinical cardiac safety testing – stem cell quality control and characterisation
09.50-10.10 Roslin Cells: Manufacturing best practice to ensure quality control, regulatory compliance and commercial success
10.10-10.25 Horizon 2020: Opportunities for funding through consortia in Regenerative Medicine
10.25-10.40 Break & Networking
10.40-11.00 TC Biopharm: Clinical and commercial success of developing cell-derived immunotherapies in Scotland. View the presentation here.
11.00-11.15 Edinburgh BioQuarter: Collaborative opportunities at the MRC CRM. View the presentation here.
11.15-11.35 John Casey: Pancreatic islet transplantation for Type 1 Diabetes
11.35-11.55 Will Shu: 3D cell printing
11.55-12.15 BioGelX: Viable 3D cell culture: tuneable and functional peptide gels. View the presentation here.
12.15-12.20 SDI: Closing remarks
12.20-13.00 Networking & Lunch
13.00-15.30 One-to-One Partnering
The following Scottish companies and academics will be attending this meeting:

  • BioGelX – David Lightbody (CEO): Develops and supplies tuneable and functional peptide gels for use as tissue mimics for specific cell type environments.
  • Roslin Cells – Aidan Courtney (CEO): Specialist services for the development and manufacture of new cell therapies and stem cell research using world leading isolation of new clinical grade pluripotent and multipotent stem cells.
  • Sistemic – Daria Olijnyk (Senior Staff Scientist): Specialist contract research, discovery and development services based on a proprietary position around micro RNAs allowing stem cell identification, process characterisation and directed differentiation.
  • TC Biopharm – Mike Leek (CEO): Start-up biotechnology company developing a novel anti-cancer immunotherapy using patients’ own immune cells for the treatment of various different types of cancer.
  • Clyde Biosciences – Margaret-Anne Craig (CEO): A contract research organisation supporting early stage drug development and cell line quality control and characterisation by providing accurate, high throughput information about the effect of their proprietary Celloptiq system on ion channels.
  • John Casey – University of Edinburgh/NHS Lothian: Consultant Transplant Surgeon at the Royal Infirmary of Edinburgh where he leads on the islet transplantation programme for Type 1 Diabetes and has helped to establish an islet isolation facility in Edinburgh.
  • Will Shu – Heriot-Watt University: Reader in Microengineering within the Biomedical Microengineering Group at Heriot-Watt University in Edinburgh where he has pioneered the development of a valve-based cell printing technique that can produce viable and functional cells in a 3D system.

Participation
For members: Free of charge (late cancellation*/no-show fee DKK 500 ex VAT)
For non-members: Free of charge (late cancellation*/no-show fee DKK 500 ex VAT)
Registration ends February 26, 2014.
* If you cancel after the registration ends, it is considered late cancellation.
This Boost Seminar is in collaboration with Scottish Development International 

About Scotland’s Stem Cell & Regenerative Medicine Industry
Scotland has an enviable track record in bringing cell therapies into the clinic with nine therapies in routine clinical practice or undergoing clinical trials for an array of indications including diabetes Type 1, corneal blindness, ischemic stroke, and melanoma.  The enviable infrastructure to implement successful clinical trials  is supported by a dynamic commercial landscape of over 30 companies that provide unique solutions across the whole supply chain including; cell line supplies, screening, characterization, GMP manufacturing, QA/QC and a range of enabling technologies and other supporting services.
The Scottish stem cell community continues to be at the forefront of innovation with novel technologies such as the world’s first 3D printing technique that produces viable clusters of primary cells or the production of stem cell derived blood that could lead to manufactured blood on an industrial scale.
Like Denmark and Sweden, Scotland’s stem cell and regenerative medicine industry is thriving. Scotland is home to one of the largest stem cell clusters in Europe which has made it one of Europe’s leading locations for the development of stem cell applications. Building on this expertise, Scotland’s stem cell and regenerative medicine industry would like to pave the way for Scottish and Nordic life sciences companies to forge stronger relationships between these pioneering countries.
About Scottish Development International
Scottish Development International (SDI) is Scotland’s economic development agency assisting in the growth of the Scottish economy by helping Scottish-based companies develop international trade and encouraging inward investment. SDI has a dedicated life sciences team that can help your company or project benefit from the business and research opportunities available in Scotland. In the regenerative medicine industry, SDI can help you to identify commercial, clinical or academic partners who can provide solutions for cell therapy clinical trials, cell line manufacturing, clinical and translational research, and stem cell technology research and development.